1010 related articles for article (PubMed ID: 22885699)
1. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics.
Schmitz R; Young RM; Ceribelli M; Jhavar S; Xiao W; Zhang M; Wright G; Shaffer AL; Hodson DJ; Buras E; Liu X; Powell J; Yang Y; Xu W; Zhao H; Kohlhammer H; Rosenwald A; Kluin P; Müller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Ogwang MD; Reynolds SJ; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pittaluga S; Wilson W; Waldmann TA; Rowe M; Mbulaiteye SM; Rickinson AB; Staudt LM
Nature; 2012 Oct; 490(7418):116-20. PubMed ID: 22885699
[TBL] [Abstract][Full Text] [Related]
2. Relevance of ID3-TCF3-CCND3 pathway mutations in pediatric aggressive B-cell lymphoma treated according to the non-Hodgkin Lymphoma Berlin-Frankfurt-Münster protocols.
Rohde M; Bonn BR; Zimmermann M; Lange J; Möricke A; Klapper W; Oschlies I; Szczepanowski M; Nagel I; Schrappe M; ; ; Loeffler M; Siebert R; Reiter A; Burkhardt B
Haematologica; 2017 Jun; 102(6):1091-1098. PubMed ID: 28209658
[TBL] [Abstract][Full Text] [Related]
3. Genetic sequencing studies in Burkitt's lymphoma: what can we learn about tumorigenesis?
Soldini D; Campo E
Expert Rev Hematol; 2013 Jun; 6(3):219-21. PubMed ID: 23782073
[No Abstract] [Full Text] [Related]
4. Oncogenic mechanisms in Burkitt lymphoma.
Schmitz R; Ceribelli M; Pittaluga S; Wright G; Staudt LM
Cold Spring Harb Perspect Med; 2014 Feb; 4(2):. PubMed ID: 24492847
[TBL] [Abstract][Full Text] [Related]
5. Sporadic and endemic Burkitt lymphoma have frequent
Zhou P; Blain AE; Newman AM; Zaka M; Chagaluka G; Adlar FR; Offor UT; Broadbent C; Chaytor L; Whitehead A; Hall A; O'Connor H; Van Noorden S; Lampert I; Bailey S; Molyneux E; Bacon CM; Bomken S; Rand V
Blood Adv; 2019 Jul; 3(14):2118-2127. PubMed ID: 31300419
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus status of sporadic Burkitt lymphoma is associated with patient age and mutational features.
Richter J; John K; Staiger AM; Rosenwald A; Kurz K; Michgehl U; Ott G; Franzenburg S; Kohler C; Finger J; Oschlies I; Paul U; Siebert R; Spang R; Burkhardt B; Klapper W
Br J Haematol; 2022 Feb; 196(3):681-689. PubMed ID: 34617271
[TBL] [Abstract][Full Text] [Related]
7. Burkitt lymphoma-related
Yamazaki T; Liu L; Conlon EG; Manley JL
RNA Biol; 2020 Oct; 17(10):1383-1390. PubMed ID: 32449435
[TBL] [Abstract][Full Text] [Related]
8. [Molecular genetic features of sporadic Burkitt's lymphoma in children].
Yang WP; Huang H; Gong LP; Wu Y; Xu HY; Zou Y; Lü BB; Zhong HS; Deng QQ; Xiao Q; Zeng ST; Zhu CD
Zhonghua Bing Li Xue Za Zhi; 2010 Dec; 39(12):819-24. PubMed ID: 21215097
[TBL] [Abstract][Full Text] [Related]
9. SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Wilke AC; Doebele C; Zindel A; Lee KS; Rieke SA; Ceribelli M; Comoglio F; Phelan JD; Wang JQ; Pikman Y; Jahn D; Häupl B; Schneider C; Scheich S; Tosto FA; Bohnenberger H; Stauder P; Schnütgen F; Slabicki M; Coulibaly ZA; Wolf S; Bojarczuk K; Chapuy B; Brandts CH; Stroebel P; Lewis CA; Engelke M; Xu X; Kim H; Dang TH; Schmitz R; Hodson DJ; Stegmaier K; Urlaub H; Serve H; Schmitt CA; Kreuz F; Knittel G; Rabinowitz JD; Reinhardt HC; Vander Heiden MG; Thomas C; Staudt LM; Zenz T; Oellerich T
Blood; 2022 Jan; 139(4):538-553. PubMed ID: 34624079
[TBL] [Abstract][Full Text] [Related]
10. Antiproliferative function of p27kip1 is frequently inhibited in highly malignant Burkitt's lymphoma cells.
Barnouin K; Fredersdorf S; Eddaoudi A; Mittnacht S; Pan LX; Du MQ; Lu X
Oncogene; 1999 Nov; 18(46):6388-97. PubMed ID: 10597239
[TBL] [Abstract][Full Text] [Related]
11. The combined expression of VPREB3 and ID3 represents a new helpful tool for the routine diagnosis of mature aggressive B-cell lymphomas.
Soldini D; Georgis A; Montagna C; Schüffler PJ; Martin V; Curioni-Fontecedro A; Martinez A; Tinguely M
Hematol Oncol; 2014 Sep; 32(3):120-5. PubMed ID: 24493312
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid induces persistent, RARalpha-mediated anti-proliferative responses in Epstein-Barr virus-immortalized b lymphoblasts carrying an activated C-MYC oncogene but not in Burkitt's lymphoma cell lines.
Cariati R; Zancai P; Quaia M; Cutrona G; Giannini F; Rizzo S; Boiocchi M; Dolcetti R
Int J Cancer; 2000 May; 86(3):375-84. PubMed ID: 10760826
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival.
Corso J; Pan KT; Walter R; Doebele C; Mohr S; Bohnenberger H; Ströbel P; Lenz C; Slabicki M; Hüllein J; Comoglio F; Rieger MA; Zenz T; Wienands J; Engelke M; Serve H; Urlaub H; Oellerich T
Proc Natl Acad Sci U S A; 2016 May; 113(20):5688-93. PubMed ID: 27155012
[TBL] [Abstract][Full Text] [Related]
14. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
15. ID3 mutations are recurrent events in double-hit B-cell lymphomas.
Gebauer N; Bernard V; Feller AC; Merz H
Anticancer Res; 2013 Nov; 33(11):4771-8. PubMed ID: 24222112
[TBL] [Abstract][Full Text] [Related]
16. Oncogenically active MYD88 mutations in human lymphoma.
Ngo VN; Young RM; Schmitz R; Jhavar S; Xiao W; Lim KH; Kohlhammer H; Xu W; Yang Y; Zhao H; Shaffer AL; Romesser P; Wright G; Powell J; Rosenwald A; Muller-Hermelink HK; Ott G; Gascoyne RD; Connors JM; Rimsza LM; Campo E; Jaffe ES; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Staudt LM
Nature; 2011 Feb; 470(7332):115-9. PubMed ID: 21179087
[TBL] [Abstract][Full Text] [Related]
17. Burkitt lymphoma: bridging the gap between advances in molecular biology and therapy.
Zayac AS; Olszewski AJ
Leuk Lymphoma; 2020 Aug; 61(8):1784-1796. PubMed ID: 32255708
[TBL] [Abstract][Full Text] [Related]
18. HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling.
Walter R; Pan KT; Doebele C; Comoglio F; Tomska K; Bohnenberger H; Young RM; Jacobs L; Keller U; Bönig H; Engelke M; Rosenwald A; Urlaub H; Staudt LM; Serve H; Zenz T; Oellerich T
Blood; 2017 Feb; 129(5):598-608. PubMed ID: 28064214
[TBL] [Abstract][Full Text] [Related]
19. Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma.
Amato T; Abate F; Piccaluga P; Iacono M; Fallerini C; Renieri A; De Falco G; Ambrosio MR; Mourmouras V; Ogwang M; Calbi V; Rabadan R; Hummel M; Pileri S; Leoncini L; Bellan C
Am J Clin Pathol; 2016 Jan; 145(1):116-27. PubMed ID: 26712879
[TBL] [Abstract][Full Text] [Related]
20. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
